ScholarIQanswers from OpenAlex

Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA

PaperCitations, authors & open-access status

Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA is a paper indexed in ScholarIQ from OpenAlex.

How many citations does Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA have?

ScholarIQcitation count

Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA has 13 citations in the OpenAlex counts ScholarIQ stores.

When was Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA published?

ScholarIQyear

Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA has 2022 year in the ScholarIQ index.

What is the open-access status of Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA?

ScholarIQoa status

Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA has closed oa status in the ScholarIQ index.

What is the DOI of Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA?

ScholarIQdoi

The DOI for Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA is on the source record.

What is the PMID of Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA?

ScholarIQpmid

The PMID for Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA is on the source record.

What is the OpenAlex record for Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA?

ScholarIQopenalex

The OpenAlex for Long-Term Trends in Risk Factor Management in Respondents with Chronic Kidney Disease in the USA is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial